Negative in Ames, human lymphocyte chromosomal aberration and rat bone marrow micronucleus assays
“Gedatolisib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay and not clastogenic in a human lymphocyte chromosomal aberration assay. Gedatolisib was not genotoxic in the in vivo rat bone marrow micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“In accordance with ICH S9 on the Nonclinical Evaluation for Anticancer Pharmaceuticals, no carcinogenicity studies have been conducted with gedatolisib.”
✓ VerifiedFDA multi-discipline review, p. 78Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Not conducted: no fertility or EFD studies (advanced cancer; given with drugs known to cause EFD toxicity)
“Fertility and early embryonic development studies are not required as gedatolisib is indicated for the treatment of patients with advanced cancer. In addition, embryo-fetal development studies were not conducted as gedatolisib will be administered in combination with palbociclib and fulvestrant, both of which are known to cause embryo-fetal developmental toxicities.”
✓ VerifiedFDA multi-discipline review, p. 78Source ↗
Safety pharmacology
Dog CV study: 5 mg/kg raised heart rate (24%) and blood pressure (6%); no QTc or other ECG effects
“In a single dose safety pharmacology study, a 5 mg/kg IV dose of gedatolisib administered to dogs increased heart rate (24%) and arterial blood pressure (6%) compared to control 12- to 33-hours post-dose, without an effect on QTc prolongation or other ECG parameters.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Genotox: Ames
Negative
“Gedatolisib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay and not clastogenic in a human lymphocyte chromosomal aberration assay.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Genotox: in vitro mammalian
Human lymphocyte chromosomal aberration: negative
“Gedatolisib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay and not clastogenic in a human lymphocyte chromosomal aberration assay.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Genotox: in vivo
Rat bone marrow micronucleus: negative
“Gedatolisib was not genotoxic in the in vivo rat bone marrow micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Carcinogenicity model
Not conducted (ICH S9, advanced cancer)
“In accordance with ICH S9 on the Nonclinical Evaluation for Anticancer Pharmaceuticals, no carcinogenicity studies have been conducted with gedatolisib.”
✓ VerifiedFDA multi-discipline review, p. 78Source ↗
Carcinogenicity timing
Not required (ICH S9, advanced cancer)
“In accordance with ICH S9 on the Nonclinical Evaluation for Anticancer Pharmaceuticals, no carcinogenicity studies have been conducted with gedatolisib.”
✓ VerifiedFDA multi-discipline review, p. 78Source ↗
hERG / QT
No hERG inhibition in vitro; no QTc prolongation or arrhythmias in dogs
“Gedatolisib produced no inhibition of human ether-a-go-go-related gene (hERG) potassium ion channel in vitro (RPT-76804/4.2.1.3), and no remarkable changes in electrocardiogram (ECG) parameters, including no evidence of QTc prolongation or arrhythmias at any dose in dogs (RPT-76613/4.2.1.3).”
✓ VerifiedFDA multi-discipline review, p. 51Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative